PREVENTION OF LIVER CANCER--EAST ASIANS IN PHILADELPHIA

预防肝癌——费城的东亚人

• 批准号: 3185288
• 负责人: William Thomas LONDON
• 金额: $ 27.56万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-05-15 至 1992-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3185288
• 关键词: East Indian; alpha fetoprotein; cancer prevention; cancer risk; disease /disorder model; disease carrier state; ferritin; hepatitis B virus group; hepatocellular carcinoma; human subject; monoclonal antibody; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology

Primary hepatocellular carcinoma (PHC) is one of the most common cancers in the world. Clinically identified tumors are uniformly lethal. However, a high-risk population for PHC has been defined, and a serological marker identified. At high risk are chronic carriers of hepatitis B virus (HBV), and rises in the serum alpha fetoprotein (AFP) levels indicate early PHC's. Such tumors are small and easily resectable; the patients have a good prognosis. Therefore, PHC presents a unique opportunity to develop a model cancer control research progress. This application details a cancer control program based on a two-step approach: 1) identification of the HBV carriers; and 2) monitoring the AFP levels of HBV carriers. Characteristic changes in AFP levels allow PHC's to be detected at an early, resectable stage. The objectives are: 1) To identify 5000 HBV carriers within the east Asian populations of the Philadelphia area. East Asian populations have high HBV carrier rates and are, therefore, the focus of the screening effort. 2) To detect 10 resectable PHC's per year among the monitored population. 3) To compare the survival of the resected patients with the survival of non-resected patients listed in the New Jersey and Pennsylvania tumor registries. 4) To evaluate screening tests for PHC other than AFP; specifically, serum ferritin levels, monoclonal antibodies to PHC ferritin and serum epoxide hydrolase. A Liver Cancer Prevention Center (LCPC) has been established at Fox Chase Cancer Center (FCCC). The HBV carriers will be identified through the Philadelphia Health Department clinics, church screenings, private physician referrals and testing at the LCPC. Carriers will be monitored at six-month intervals at the LCPC for AFP elevation. Persons with characteristic AFP elevations will undergo scanning and other diagnostic procedures for PHC. All treatment and follow-up will be carried out at the FCCC.

原发性肝细胞癌（PHC）是世界上最常见的恶性肿瘤之一， 世界 临床上鉴定的肿瘤都是致命的。 但 肝癌的高危人群已经确定， 鉴定 高风险的是B型肝炎病毒（HBV）的慢性携带者， 血清甲胎蛋白（AFP）水平的升高表明早期 原发性肝癌。 这种肿瘤很小，很容易切除;患者有一个 预后良好。 因此，初级保健提供了一个独特的机会， 模型癌症控制研究进展。 该应用程序详细介绍了一个癌症控制计划的基础上，两步 方法：1）HBV携带者的识别; 2）AFP监测 HBV携带者的水平。 甲胎蛋白水平的特征性变化 可以在早期发现，可以切除 目标是：1） 在东亚人群中确定5000名HBV携带者， 费城地区 东亚人群HBV携带率高， 因此，是筛选工作的重点。 2)检测10 可切除的肝癌的数量。 3)比较 切除患者的生存率与未切除患者的生存率 在新泽西和宾夕法尼亚肿瘤登记处列出的患者。 4)到 评价除AFP外的PHC筛查试验;特别是血清 铁蛋白水平、PHC铁蛋白单克隆抗体和血清环氧化物 水解酶。 在福克斯蔡斯建立了肝癌预防中心（LCPC） 癌症中心（FCCC）。 乙肝病毒携带者将通过 费城卫生部诊所，教堂筛查，私人 医生转诊和LCPC的测试。 承运人将被监测， 每隔六个月在LCPC进行AFP升高。 人 特征性AFP升高将进行扫描和其他诊断 PHC的程序。 所有治疗和随访将在 FCCC. 1998 - 1999年